SCHEDULE: Goldman Sachs Reports Stake in Agilon Health

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, disclosing beneficial ownership of 6.1% of Agilon Health, Inc. common stock as of March 31, 2026.

Summary

• This filing is a Schedule 13G, indicating that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC beneficially own a significant stake in Agilon Health, Inc.
• As of March 31, 2026, the reporting persons collectively hold 1,018,303.08 shares of Agilon Health's common stock.
• This holding represents 6.1% of the total class of securities.
• The filing clarifies that The Goldman Sachs Group, Inc. is a parent holding company and Goldman Sachs & Co. LLC is a broker-dealer and investment adviser, a subsidiary of the former.
• The securities are held in the ordinary course of business and not for the purpose of influencing control of Agilon Health.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. While it indicates significant institutional interest from Goldman Sachs, it does not provide operational or financial performance data for Agilon Health itself.

Positives

• Goldman Sachs, a major financial institution, has taken a notable position in Agilon Health, potentially signaling confidence in the company's prospects.
• The filing confirms a substantial beneficial ownership of 6.1%, indicating a significant investment.

Negatives

• The filing does not contain any negative financial or operational information about Agilon Health; it solely reports ownership.

Risks

• The primary risk associated with this filing is the potential for significant share price movement if Goldman Sachs decides to alter its holdings, given its substantial stake.
• As a large institutional holder, any strategic shift by Goldman Sachs could impact market perception and liquidity for Agilon Health's stock.

Future Outlook

The filing does not contain forward-looking statements or guidance from Agilon Health. It solely reports on the ownership stake held by Goldman Sachs.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major financial institution like Goldman Sachs often indicates a significant investment thesis. For Agilon Health, this could signal increased institutional interest and potential validation of its business model within the healthcare services sector.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, potentially leading to greater liquidity and market attention. However, it also means a significant portion of the company is held by one entity.
• Employees: No direct impact mentioned in the filing.
• Customers: No direct impact mentioned in the filing.
• Suppliers: No direct impact mentioned in the filing.
• Creditors: No direct impact mentioned in the filing.

Next Steps

• Monitor future filings by Goldman Sachs for any changes in their beneficial ownership of Agilon Health.
• Observe Agilon Health's subsequent financial reports and strategic announcements for performance indicators.

Key Dates

Recommendation

This filing is a disclosure of ownership and does not contain performance data or forward-looking guidance for Agilon Health. While Goldman Sachs' significant stake is noteworthy, a 'hold' recommendation is appropriate as it does not provide sufficient information to warrant a buy or sell decision based solely on this document.

Keywords

Agilon Health, Schedule 13G, Goldman Sachs, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment